Announcements Trials
Browse Landscape

Phase

Phase 1/2 1Phase 1 1

Status

Completed 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

CNS 2Sarcoma 1

Conditions

Multiple Myeloma 5Recurrence 3Lymphoma 3Glioblastoma 3Neoplasms 2Lymphoma, T-Cell, Cutaneous 2Lymphoma, B-Cell, Marginal Zone 2Glioma 2Brain Neoplasms 2Pancreatic Neoplasms 1Neoplasms, Plasma Cell 1Melanoma 1Leukemia 1Gliosarcoma 1Ependymoma 1Disease Progression 1Diffuse Intrinsic Pontine Glioma 1Carcinoma, Non-Small-Cell Lung 1

Interventions

Temozolomide 162Radiosurgery 114Radiotherapy 99Bevacizumab 95Magnetic Resonance Spectroscopy 64Carboplatin 48Etoposide 34Surgical Procedures, Operative 33Irinotecan 33pembrolizumab 32Nivolumab 32Cyclophosphamide 32Erlotinib Hydrochloride 31Radiation 29Carmustine 28Cisplatin 25Lomustine 24Trastuzumab 23Ipilimumab 23Filgrastim 23Vincristine 20Mental Status and Dementia Tests 20Aminolevulinic Acid 19Topotecan 18Pemetrexed 18Capecitabine 18Specimen Handling 17Sorafenib 15Radiotherapy, Intensity-Modulated 15Imatinib Mesylate 15

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Interventional × Brain Neoplasms × marizomib × Clear all
NCT02330562 2022-06-08

Stage 1: Marizomib + Bevacizumab in WHO Gr IV GBM; Stage 2: Marizomib Alone; Stage 3: Combination of Marizomib and Bevacizumab

Celgene

Phase 1/2 Completed
121 enrolled 27 charts
CNSSarcoma

Brain Neoplasms, Glioblastoma, Glioma, Gliosarcoma

NCT02903069 2021-04-19

Study of Marizomib With Temozolomide and Radiotherapy in Patients With Newly Diagnosed Brain Cancer

Celgene

Phase 1 Completed
66 enrolled
CNS

Brain Neoplasms, Glioblastoma, Glioma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡